Cold chain logistics boom as GLP-1 drugs surge

Shipping companies are racing to expand their cold chain logistics capacity as demand for injectable weight-loss and diabetes drugs explodes. According to CNBC, logistics giants including UPS, FedEx, DHL and C.H. Robinson are each investing hundreds of millions of dollars in temperature-controlled facilities, a shift driven almost entirely by the surge in GLP-1 medications like Ozempic, Wegovy, Mounjaro and Zepbound.

The reason is simple: most GLP-1 drugs must stay refrigerated from factory to patient, or they become useless. A single temperature breach during shipping can render an entire shipment worthless, which means the logistics companies handling them need infrastructure and expertise that most freight handlers simply do not have.

Why cold chain logistics has become a major business opportunity

Three years ago, hardly anyone outside the pharmaceutical industry thought much about cold chain logistics. Then came the Covid vaccines in 2020, which required freezing and specialized handling on a scale never attempted before. Logistics firms discovered they could build profitable, reliable networks to move ultra-sensitive cargo. But the real opportunity emerged when GLP-1 drugs, which require only refrigeration (not freezing), went mainstream.

In July 2026, a Gallup poll found that 11% of Americans are taking GLP-1 drugs for weight loss. That is up from just 3% in 2024. In two years, the number of people using these medications quadrupled. Every one of those people needs their medicine delivered cold and on time, creating unprecedented demand for the infrastructure to make that happen.

Consider the market itself. Growth Market Reports projects that temperature-sensitive biologics (a category that includes GLP-1s, insulin, some vaccines, and antibodies) will grow at 8.3% per year and reach a market value of roughly $39.1 billion by 2033. That is not just growth in the drugs themselves. That is growth in the logistics services needed to move them.

UPS made this opportunity visible in its earnings report. The company’s global healthcare portfolio has gained market share every single year since 2021. In the first quarter of 2026, UPS generated its first ever $3 billion healthcare revenue quarter. John Bolla, UPS President of Healthcare, told CNBC that healthcare companies are actively searching for logistics partners who can handle the volume. The company announced a $48 million investment in temperature-controlled facilities just in June 2026.

FedEx reported that healthcare transportation revenue in fiscal year 2026 reached nearly $10 billion. The company recently launched an entire new division dedicated to life sciences, with specialized machinery including machine learning systems that track product movement and predict problems before they happen. Nick Gennari, FedEx’s president of healthcare, noted that the company is “ideally positioned” because it already owns airlines and has scheduling advantages that competitors cannot match.

C.H. Robinson, a smaller player, surpassed $1 billion in healthcare logistics revenue over the past year, with much of that growth directly attributed to GLP-1 drugs. DHL announced plans to invest 2 billion euros (roughly $2.25 billion) in health logistics by 2030, with half of that money going to the Americas.

Why this is harder than regular shipping

The core challenge is unforgiving margins for error. A refrigerated truck that drifts to 26 degrees Celsius instead of 2 to 8 degrees for even a few hours can destroy the entire shipment. The Food and Drug Administration explicitly warns patients not to use GLP-1 drugs that arrive warm or with inadequate refrigeration.

That is not the only complication. Many specialty drugs have very short shelf lives and must be delivered within precise time windows. A drug that becomes useless in 30 days cannot sit in a warehouse for 10 days waiting for transport. The whole supply chain has to move in lockstep.

Ronnie Davis, vice president of North American surface transportation at C.H. Robinson, explained to CNBC that refrigerated resources in the logistics system are now becoming constrained. There is only so much cold storage capacity in existence. As demand from GLP-1 manufacturers grows, it puts pressure on the same limited pools of temperature-controlled trucks, planes and facilities. Logistics companies that do not build capacity now will find themselves unable to fulfill orders later.

How does cold chain logistics affect the businesses shipping the drugs?

For pharmaceutical manufacturers, reliable cold chain logistics is no longer a nice-to-have. It is a requirement for survival. If you cannot deliver your drug to patients safely, you cannot sell it. This creates leverage for logistics companies. Pharma firms must either build their own cold chain infrastructure (extremely expensive) or outsource to specialists like DHL, which now operates warehouses and manages them on behalf of clients.

On the flip side, logistics companies face enormous liability. Hendrik Venter, CEO of DHL Supply Chain, emphasized that “you cannot lose a shipment, you cannot replace it.” Every dose of a specialty drug that arrives damaged is a patient who goes without treatment. That responsibility is driving companies to invest in artificial intelligence systems that monitor temperature in real-time and alert teams to problems before they happen.

What this means for you

Cold chain logistics is an invisible infrastructure layer, but it affects anyone taking or considering a temperature-sensitive medication. Understanding how it works and what constraints exist can help you anticipate changes in drug availability and pricing.

• If you take a GLP-1 drug or are considering one: The expansion of cold chain capacity makes these medications more reliably available and less likely to arrive damaged. However, as demand grows and capacity becomes more constrained, delivery delays or shortages could emerge in certain regions before new infrastructure is built. Ordering from reliable, established logistics partners reduces that risk.
• If you hold healthcare or logistics stocks: Companies like UPS, FedEx and DHL are investing aggressively in cold chain capacity because they expect sustained, high-margin growth from specialty drugs. Earnings reports from these firms will increasingly highlight healthcare revenue as a growth driver. Watch for announcements about new temperature-controlled facilities and contracts with major pharmaceutical companies as signals of competitive positioning.
• If you are thinking about healthcare investing more broadly: The success of specialty drugs depends not just on the drug itself, but on a functioning supply chain. Logistics bottlenecks could slow the rollout of new medications or prevent certain drugs from reaching remote areas. The companies solving these logistics problems are capturing significant value, and that value is likely to grow as the market for biologics expands.

Thewealthora’s in-depth guides cover the economics of healthcare investing, how supply chains affect stock valuations, and the broader trends reshaping pharmaceutical markets.

Go deeper on Thewealthora

• Strait of Hormuz traffic recovery pushed back to 2027
• Oil prices middle east shipping risks hit six-week peak
• Oil tankers avoid Hormuz as floating storage piles up

Originally reported by CNBC. Facts verified; analysis and wording are Thewealthora’s own.

Arpit Soni

The Thewealthora desk covers markets, money and personal finance, with zero jargon and every claim sourced.